COMMUNIQUÉS West-GlobeNewswire

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
09/12/2025
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine LAI is designed to help support real [...]
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
09/12/2025
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision
09/12/2025
Company Finalizes GlycoCheck® License, Advances DocSun AI Acquisition and SDK Partnerships, and Engages Investment Bank for Planned 2026 Initiatives CHATTANOOGA, Tenn., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BioRegenx, Inc [...]
Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO
09/12/2025
SOMERVILLE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced a planned leadership transition [...]
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000 ® Index and the broad-market [...]
Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ System
09/12/2025
DURHAM, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic acids (RNA and DNA), [...]
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
09/12/2025
Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve vision ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical- [...]
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
09/12/2025
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 2025 1 , and core [...]
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
09/12/2025
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP [...]
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
09/12/2025
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. ( [...]
Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
09/12/2025
SUNRISE, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced [...]
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
09/12/2025
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of [...]
Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation
09/12/2025
AeroPace temporary transvenous diaphragm neurostimulation system now available to help critically ill patients breathe independently faster EXTON, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical , a leader in [...]
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
09/12/2025
Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage [...]
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
09/12/2025
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers [...]
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
09/12/2025
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of all responses were [...]
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
09/12/2025
Continued listing reflects progress on turnaround strategy and pipeline advancement BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology [...]
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
09/12/2025
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- [...]

Pages